King & Spalding LLP has announced the expansion in New York City of its intellectual property practice with the arrival of partner Kenneth H. Sonnenfeld, an authority on biotechnology, pharmaceutical and chemical patent prosecution, counseling and diligence.
Mr. Sonnenfeld brings to the firm's New York office the new capability of patent prosecution, which complements the firm's existing patent prosecution practice in Atlanta and supports the existing biotechnology/pharmacology patent litigation practice in New York.
Mr. Sonnenfeld, who holds a Ph.D. in pharmacology, joins King & Spalding from Morgan & Finnegan, where he was a partner. His practice focuses on biotechnology and pharmaceutical patent law, including United States and international patent prosecution, interference practice, opinions, licensing and patent litigation.
Mr. Sonnenfeld is the fourth new IP partner to join King & Spalding recently. Tony Askew, Steve Schaetzel and Jim Johnson recently joined the firm's IP practice in its Atlanta office. The group, which joined the firm from Kilpatrick Stockton LLP, significantly bolsters the firm's capabilities in patent and trademark litigation and patent prosecution, particularly in the biotechnology and pharmaceutical fields.
Joining King & Spalding's New York office with Mr. Sonnenfeld are three patent agents and an associate. They are: Jonathan Ball, associate, and Deborah Drazen, Joseph Eng, and Michael Willis, patent agents.